Concepedia

Matthew S. Davids

MS

Statistics

Publications

156

Citations

12.6K

H-Index

52

Active since

2001

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

The University of Texas MD Anderson Cancer Center

AbbVie (United States)

University of California San Diego

Matthew S. Davids is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

2001–2024

156

Publications

156

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.8K citations · Full text

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 737 citations · Full text

, , +17

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy et al. · New England Journal of Medicine · 2016 · 588 citations · Full text

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

, , +6

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 372 citations · Full text

, , +9

1–5 of 156